Proteon Pharmaceuticals consolidating its position in India
In line with its expansion plans, Proteon Pharmaceuticals India, a subsidiary of Proteon Pharmaceuticals S.A. Poland, announced the appointment of Mr. Joginder Singh Uppal as the Regional Business Director for the Indian subcontinent and South-East Asia Region. Mr. Uppal will drive growth and acquisition strategies across the regions to support the poultry, aquaculture, and dairy industries in achieving safe and sustainable production.
Over the decades, antibiotics have become a norm used in animal feed in multiple countries to promote the well-being and growth of animals. At the present juncture of time, this practice has now raised a lot of apprehensions. A priority concern has been that continuous exposure to antibiotics can contribute to antimicrobial resistance. Proteon Pharmaceuticals focuses on precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. Diseases caused by Salmonella and E. Coli are the major challenges faced by poultry producers. The infections caused by these bacteria not only impact poultry’s health but also the profitability of the producers as well as human health.
Mr. Uppal has a rich and recognized track record of more than 30+ years in sales and marketing in the Poultry and Livestock sector and has worked in varied markets across India, South Asia, the Middle East, and Africa. He has strong technical knowledge on the subject and with expertise in sales, corporate strategy, and trade management, Mr. Uppal will focus on improving organizational performance and unlocking new business opportunities through strategic alliances with key decision-makers.
Elaborating on his new role at Proteon Pharmaceuticals, Mr. Uppal commented “Phage therapy mainly utilizes lytic phages to kill their respective bacterial hosts and can be an attractive solution to combating the emergence of AMR in livestock. With an aim to provide innovative antibacterial solutions to the animal health industry; Proteon’s mission is to eliminate unnecessary antibiotic usage, reduce the risk of AMR and at the same time, increase the sustainability of protein production through the reduction of waste and in the improvement of on-farm efficiency.”
Commenting on Mr. Uppal’s appointment, Dr. Paolo Doncecchi, Global Sales Director Proteon Pharmaceuticals, said, “We are proud to induct Mr. Joginder Singh Uppal from the industry and we wish him the very best as he takes on the mantle of a challenging position of Regional Business Director. I am particularly thrilled about this critical role being fulfilled by a reputed veteran like Mr. Uppal. With his vast experience across diverse industries and work cultures, he will spearhead the next levels of growth and reinforce Proteon Pharmaceuticals as a forerunner in the bacteriophage revolution in the region. His appointment is a reinforcement of the Proteon vision to be a leader in bacteriophage research and technology with customer empowerment at the helm of it.
Mr. Nipun Gupta, CCO at Pharmaceuticals adds
“We have already launched BAFASAL+G(R) and BAFACOL(R) for poultry to control Salmonella and E. Coli respectively. We have also introduced BAFADOR(R) for Aquaculture to control Pseudomonas and Aeromonas, and very soon we will be launching BAFACAM for dairy to control mastitis. There are also many other products in the pipeline to target the pathogenic bacteria prevalent in the poultry, dairy, and aqua industry to enhance the profitability of the farm owners. With Mr. Uppal now taking charge, he already has his hands full to ensure that our products can benefit the vast number of poultry and dairy farmers as well as the growing food industry with solutions that are sustainable, non-GMO, and drive financial viability. ”
About Proteon Pharmaceuticals
Proteon Pharmaceuticals S.A. is a global leader in bacteriophage (phage) technology for livestock farming and aquaculture. Proteon’s mission is to eliminate the need for unnecessary antibiotic use, reduce the risk of antimicrobial resistance (AMR), as well as to increase the sustainability of protein production through the reduction of waste and improvement of on-farm efficiency. Proteon’s products function by modulating the microbiome enabling prophylactic health. Proteon has patented a precision phage product development platform using genomics technologies, molecular biology, bioinformatics, and artificial intelligence (AI) to create effective, reliable, and safe antibacterial solutions for animal and human health.
Website: www.proteonpharma.com
Linkedin: https://in.linkedin.com/company/proteon-pharmaceuticalsindia
